News | PET-CT | March 23, 2016

U.K. study finds non-invasive imaging effective at finding remaining head and neck cancer cells while reducing post-treatment surgeries

PET-CT, head and neck cancer, U.K. study, persistent cells

March 23, 2016 — New research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection for head and neck cancer patients. This discovery means patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells.

The study from the Universities of Birmingham and Warwick, published in the New England Journal of Medicine, used advanced imaging to identify cancer cells still present after treatment of head and neck cancer with primary chemoradiotherapy.

Previous guidelines meant that all head and neck cancer patients have to undergo neck dissection surgery, a three-hour operation with considerable morbidity and up to a one-week hospital stay, because there was no reliable way to identify which patients still had remaining cancer cells.

The use of positron emission tomography–computed tomography (PET-CT) scans for image-guided surveillance meant that routine post-treatment operations were no longer necessary, and can now be better targeted to the right areas in those 20 percent of patients who still have persistent cancer.

Prof. Hisham Mehanna, from the Institute of Head and Neck Studies and Education (InHANSE) at the University of Birmingham, explained, “After treatment, remaining cancer cells play something akin to hide and seek. Our study shows that using this PET-CT scan we can hunt them down, find them and remove them effectively.”

The study was conducted across 37 centers in the United Kingdom, overseen by Warwick Clinical Trials Unit, University of Warwick. Five hundred sixty-four patients were recruited between 2007 and 2012, with 282 in the image-guided surveillance group and 282 in the neck dissection control group.

Only 54 (19 percent) of the 282 in the image-guided surveillance group went on to undergo neck dissection surgery, compared with 221(78 percent) of the 282 in the control group.

Survival rates, quality of life and other factors were considered and remained similar across both groups.

Prof. Janet Dunn, from Warwick Clinical Trials Unit said, “This is an important study for the future management of these patients. When we first designed the study in 2007, patients were undergoing routine neck dissection and they did not have access to PET-CT. The results show that the use of PET-CT imaging can prevent unnecessary operations and reduce associated surgical complications.”

Mehanna added, “Patient outcomes, and avoiding unnecessary surgery, are the main goals of this study. But there is a cost saving to be made too. When compared with neck dissection, the PET-CT guided surveillance saved £1,492 (US$2,190) per person for the NHS. Carry that across the tens of thousands of cases each year across the world and you see a significant saving that can be redistributed into other therapies.”

Ninety percent of head and neck cancers are squamous cell carcinomas, known as head and neck squamous cell carcinomas (HNSCC). HSNCC is the sixth leading cancer by incidence across the globe, with an estimated 500,000 new cases reported each year.

The research was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme.

For more information: www.nejm.org


Related Content

News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
Subscribe Now